These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 14986275)

  • 1. Liver toxicity in epidemiological cohorts.
    Becker S
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S49-55. PubMed ID: 14986275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity with combination of valproic acid, ritonavir, and nevirapine: a case report.
    Cozza KL; Swanton EJ; Humphreys CW
    Psychosomatics; 2000; 41(5):452-3. PubMed ID: 11015639
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
    Mira JA; Macías J; Girón-González JA; Merino D; González-Serrano M; Jiménez-Mejías ME; Caballero-Granado FJ; Torre-Cisneros J; Terrón A; Becker MI; Gómez-Mateos J; Arizcorreta-Yarza A; Pineda JA;
    J Antimicrob Chemother; 2006 Jul; 58(1):140-6. PubMed ID: 16720565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    Bundow D; Rosoff L; Aboulafia DM
    AIDS Read; 2001 Nov; 11(11):577-80. PubMed ID: 11789021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
    Iveli P; Noguera-Julian A; Soler-Palacín P; Martín-Nalda A; Rovira-Girabal N; Fortuny-Guasch C; Figueras-Nadal C
    Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):39-44. PubMed ID: 25487604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
    Clarke S; Harrington P; Condon C; Kelleher D; Smith OP; Mulcahy F
    Int J STD AIDS; 2000 May; 11(5):336-7. PubMed ID: 10824944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
    Rodríguez Guardado A; Maradona Hidalgo JA; Asensi Alvarez V; Cartón Sánchez JA
    Med Clin (Barc); 2004 Mar; 122(8):317. PubMed ID: 15030745
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():14-5. PubMed ID: 12043064
    [No Abstract]   [Full Text] [Related]  

  • 13. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
    Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
    HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of nevirapine in pregnancy.
    Natarajan U; Pym A; McDonald C; Velisetty P; Edwards SG; Hay P; Welch J; de Ruiter A; Taylor GP; Anderson J
    HIV Med; 2007 Jan; 8(1):64-9. PubMed ID: 17305934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
    Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.
    Johnson S; Chan J; Bennett CL
    Ann Intern Med; 2002 Jul; 137(2):146-7. PubMed ID: 12118982
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
    Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
    HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Shahar E; Krivoy N; Weltfriend S; Pollack S
    Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Dieterich DT; Robinson PA; Love J; Stern JO
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S80-9. PubMed ID: 14986279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.